补充维生素D对肝硬化患者血糖指数、血脂谱及肝功能检查的影响：一项双盲随机对照试验。

Effects of vitamin D supplementation on the glycaemic indices, lipid profile and liver function tests in patients with cirrhosis: a double-blind randomised controlled trial.

作者信息

Derogar Kasmaei Seyedeh Roghayeh, Parastouei Karim, Hosseini Ahangar Behnam, Saberifiroozi Mehdi, Taghdir Maryam

机构信息

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

出版信息

BMJ Nutr Prev Health. 2024 Aug 30;7(2):e000938. doi: 10.1136/bmjnph-2024-000938. eCollection 2024.

DOI:10.1136/bmjnph-2024-000938

PMID:39882304

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11773653/

Abstract

BACKGROUND

Liver cirrhosis is considered a progressive disease that can eventually result in death. Vitamin D deficiency is prevalent in patients with cirrhosis. Few studies have been conducted on the effect of vitamin D supplementation in patients with cirrhosis.

OBJECTIVES

The aim of this study was to identify the effect of vitamin D supplementation on lipid profile, glycaemic indices and liver function tests in patients with cirrhosis.

METHODS

Sixty patients with cirrhosis were involved in this double-blind, randomised controlled clinical trial. During the intervention, patients received one 50 000 IU pearl of vitamin D supplement or placebo per week for 12 weeks. Before and after supplementation, we assessed serum 25-hydroxy-vitamin-D3 (25(OH) D3), glycaemic indices (insulin, haemoglobin A1c, fasting blood glucose (FBG) and homeostatic model assessment for insulin resistance (HOMA-IR)), lipid profile and liver function tests.

RESULTS

Baseline variables were not significantly different between groups. The present study indicated that over the 12 weeks, vitamin D supplementation significantly increased serum 25(OH) D3 (p<0.001), and also significantly decreased FBG (p=0.006), and HOMA-IR (p=0.001).

CONCLUSIONS

Vitamin D supplementation significantly improves FBG and HOMA-IR as well as serum 25(OH) D in patients with cirrhosis.

TRIAL REGISTRATION NUMBER

The protocol of the study was registered at the Iranian Registry of Clinical Trials (IRCT) (IRCT20140502017522N2).

摘要

背景

肝硬化被认为是一种可最终导致死亡的进行性疾病。维生素D缺乏在肝硬化患者中普遍存在。关于补充维生素D对肝硬化患者影响的研究较少。

目的

本研究旨在确定补充维生素D对肝硬化患者血脂谱、血糖指标和肝功能检查的影响。

方法

60例肝硬化患者参与了这项双盲、随机对照临床试验。在干预期间，患者每周接受一粒50000IU的维生素D补充剂或安慰剂，共12周。在补充前后，我们评估了血清25-羟基维生素D3（25(OH)D3）、血糖指标（胰岛素、糖化血红蛋白、空腹血糖（FBG）和胰岛素抵抗稳态模型评估（HOMA-IR））、血脂谱和肝功能检查。